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Abstract Prion diseases are clinically diagnosed and con-
firmed upon post-mortem histopathological examination of
brain tissue. The only reliable molecular marker for prion
diseases is abnormal prion protein (PrPSc), a pathologically
conformed prion protein that primarily accumulates in the
central nervous system and to a lesser extent in
lymphoreticular tissues. However, the use of PrPSc as a mark-
er for preclinical diagnoses is limited because the concentra-
tion of PrPSc in easily accessible body fluids is extremely low.
Hence, one of the most promising approaches would be the
development of an efficient in vitro amplification method for
PrPSc. Indeed, protein misfolding cyclic amplification
(PMCA) has become an important diagnostic tool for prion
diseases. Here, we first describe a new superior PMCA device
that employs electricity (referred to as ePMCA) to amplify
PrPSc. The ePMCA device markedly improved the detection
limit for PrPSc by amplifying trace amounts of pathogenic
prion protein by applying electricity to improve PMCA. To
increase the cavitation of sonication, a glass sample tube was
used, and the upper side of the horn was shaped such that it
had a curved cross-section. The ePMCA device enabled
PrPSc to be amplified even from a sample seeded with 10–
28-fold diluted 263K scrapie-infected brain homogenates with
recombinant hamster prion protein (rHaPrP). In addition, the
efficiency of prion amplification was best when 50 mM
HEPES and 1% Triton X-100 were used as a PMCA conver-
sion buffer in the various conditions that we applied. These
results indicate that ePMCA would be very valuable for the
rapid and specific diagnosis of human prion diseases and,
thus, may provide a practically improved method for antemor-
tem diagnoses using the body fluids of patients and animals
with prion disease.
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Introduction
Transmissible spongiform encephalopathies (TSEs), or prion
diseases, make up a group of neurodegenerative disorders that
include Creutzfeldt–Jakob disease (CJD) in humans, bovine
spongiform encephalopathy (BSE) in cattle, and scrapie in
sheep [1, 2]. The etiological agent of prion disease is an ab-
normal prion protein (PrPSc), which is an abnormal isoform
that is converted from the normal cellular protein (PrPC) by
unknown post-translational modification processes. To date,
human prion diseases are confirmed only by detecting PrPSc
via post-mortem histopathological examination of brain tis-
sues. The diagnosis of CJD is difficult because PrPC is not
sufficiently converted to PrPSc at the early stage of prion dis-
ease. Thus, various trials have been conducted to develop a
diagnostic method with high sensitivity and accuracy for
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detecting trace amounts of PrPSc [3–5]. In recent studies, di-
agnostic methods that amplify pathogenic PrPSc, such as pro-
tein misfolding cyclic amplification (PMCA) and quaking-
induced conversion (QUIC), have been investigated [5–8].
Since PMCA was first reported in 2001, many studies based
on PMCA have been conducted [3, 9–16]. Some researchers
have detected PrPSc in body fluids such as the cerebrospinal
fluid, blood, and urine, which can be more easily obtained
than the brain tissue [9–14], and early diagnoses in animals
using blood samples have been demonstrated [10, 11]. In
2011, a new technique referred to as PMCAb, wherein
Teflon beads (McMaster-Carr, Los Angeles, CA) were added
to the PMCA reaction to increase the efficiency of PrPSc am-
plification, was developed [15]. Many research teams were
later able to detect pathogenic prion protein in specific prion
infectious body fluids, such as the urine, blood, and saliva,
utilizing PMCA devices [10–13, 16]. Therefore, we attempted
to conduct experiments using a Misonix model S-4000
sonicator to amplify PrPSc; however, more advanced methods
for the early diagnosis of prion diseases need to be developed,
as there is a lack of consistency among the results of experi-
ments that have used PMCA devices. We sought to improve
the amplification of pathogenic prion protein by using elec-
tricity (termed ePMCA). Here, we show that this technical
improvement can be employed to overcome the limitations
unique to conventional PMCA, i.e., that the amplification ef-
ficiency of PMCA strongly depends on the tube position,
which results from the differential cavitation induced by the
different distances of each tube from the horn center [15]. The
improved ePMCA technique can also be used to simulta-
neously amplify PrPSc from very high dilutions of infected
brain homogenate. The aim of this study was to determine
the conditions that stimulate PrPSc amplification using the
ePMCA technique and a conversion buffer. Supplementing
the procedure with electricity resulted in remarkable improve-
ments in the yield and reproduction rate of prion conversion
and in the sensitivity of PrPSc detection. Here, we show that
simple modification of the PMCA procedure can be imple-
mented to overcome the drawbacks associated with PMCA
and that ePMCA can be utilized for the early diagnosis of
prion disease in animals and humans.
Materials and Methods
Animals and Scrapie Strains
Weused 6-week-old inbredmice (C57BL/6J and ICR) and gold-
en Syrian hamsters (SHa) from the SLC (Japan), which were
divided into a group for infectionwith scrapie strains and a group
of age-matched controls. Theoriginal stockof scrapie strainswas
provided by Dr. Alan Dickinson (Neuropathogenesis Unit,
Edinburgh, Scotland). All passages were performed by
intracerebral inoculation with 30 μl (mice) or 50 μl (SHa) of 1%
(w/v) brain homogenates in 0.01 M phosphate-buffered saline
(PBS, pH 7.4) obtained from the scrapie-infected brains at the
terminal stage of the disease. We isolated the brains from the
experimental animals when clinical symptoms were clearly evi-
dent, which was at 70 days post-inoculation (dpi) for the 263K
scrapie-infected hamsters and at 158 dpi for the ME7 scrapie-
infected mice. For Western blots, the brains from scrapie-
infected animals and age-matched controls were frozen without
perfusion and stored at−70 °C prior to use. Each experimentwas
repeated at least three times. All animal experiments were con-
ducted in accordancewith the guidelines set forth by theNational
InstitutesofHealth(NIHguidefor theCareandUseofLaboratory
Animals, USA) and by the Hallym Medical Center for
Institutional Animal Care and Use Committee. The brains were
placed in the chosen conversion buffer during each experiment
and homogenized gently using a glass homogenizer (Corning,
USA) to a concentration of 10% (w/v). Crude brain homogenates
were centrifuged at 1500 rpm for 30 s at 4 °C. The supernatants
were used as brain homogenates.
Recombinant Prion Protein
Recombinant hamster PrP (rHaPrP), a plasmid containingDNA
sequences coding for residues 23–231 of the hamster PrP se-
quence,wasexpressed, refolded into a soluble form, andpurified
as described previously [7]. We amplified DNA sequences cod-
ing for hamster PrP residues 23–231 by PCR, ligated them into
the pET41 vector (EMD Biosciences, USA) as NdeI-HindIII
inserts, andverified their sequences.After transforming the plas-
mids intoEscherichiacoliBL21(DE3)cells (EMDBiosciences,
USA), we expressed host-encoded cellular prion protein (PrP-
sen) and lysed cell pellets with BugBuster and lysonase (EMD
Biosciences,USA) in the presence ofEDTA-freeprotease inhib-
itors (Roche, Germany), washed the recombinant prion protein
(rPrP)sen inclusion bodies twice with 0.1 × BugBuster, and
pelleted them by centrifugation. We purified the enriched rPrP
according to a previously describedmethod [8]with someminor
modifications. We loaded a Ni-NTA Superflow resin (Qiagen,
Germany) with denatured protein from the inclusion bodies and
refolded theproteinwitha lineargradientover6hat a flowrateof
1.0 ml/min using an AKTA Purifier system (GE Healthcare,
USA). We then eluted the rPrP proteins with 100 mM sodium
phosphate (pH 5.8), 500 mM imidazole, and 10 mM Tris. We
filteredanddialyzedthemagainst10mMphosphate(pH5.8)and
then determined the concentration of rPrP. Aliquots of the pro-
teins were stored at −70 °C after purification.
The Combination of Surfactants and Buffer Solution
Thebuffer solution used for thePMCAmethodwas termedas a
conversion buffer, as previously described [17].We performed
the PMCA method using different buffer solutions, such as
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2-(N-morpholino)ethanesulfonic acid (MES), piperazine-N,N
″-bis(2-ethanesulfonic acid) (PIPES), N-2-acetamido-2-
aminoethanesulfonic acid (ACES), 3-(N-morpholino)-2-





er was as follows: 150 mMNaCl, 50 mMHEPES pH 7.0, 1%
Triton X-100, and an EDTA-free protease inhibitor cocktail
(Roche, Germany) per 50 ml of conversion buffer [18]. We
performed the experiments using different concentrations of
these HEPES buffer solutions ranging from 50 to 500mM.
PMCATechniques: Conventional PMCA, Ilsong PMCA,
and ePMCA
To avoid contamination, the preparation of noninfectious ma-
terial was conducted inside a biological safety cabinet in a
prion-free laboratory, and aerosol-resistant tips were used.
The bench, pipettes, and other equipment were cleaned fre-
quently with alcohol or bleach. The resulting 10% normal
mouse brain homogenate in conversion buffer was used as
the substrate in the Ilsong and Misonix S-4000 PMCA reac-
tions. To prepare seeds, 10% scrapie brain homogenate in
conversion buffer was serially diluted 103- to 108-fold, as
indicated, in the conversion buffer, and 10-μl samples of the
dilutions were used to seed 90 μl of normal mouse brain
homogenate in the Ilsong and Misonix S-4000 PMCA de-
vices. Samples in thin-wall 200-μl PCR tubes were placed
in a rack fixed inside the Ilsong and Misonix S-4000 micro-
plate horns. The sonicator was programmed to perform 96
repeated cycles of 1 min of sonication followed by 29 min
of incubation, and the output was set to 50%. One round of the
PMCA procedure consisted of a 48-h reaction comprising
96 cycles of sonication and incubation. The PMCA method
consists of the repetition of 1 cycle of incubation and sonica-
tion. Electricity at 24VDC/30Wwas applied to the glass tube
for 29min, and then the tube was incubated at 37 °C in a water
circulation system, and the ultra-wave sonication was adjusted
during the last 1 min. We optimized the power of ultra-wave
sonication by 50% to fit the experiment. At temperatures over
37 °C, the moisture was increased and evaporated into the lid
of the tube, causing an imbalance in the inside of the tube and
experimental samples. Thus, the inside of the tube, including
the experiment samples, is not constant, and the amplification
efficiency decreases as the content at the bottom of the tube
upon applying the ultra-wave becomes thicker due to evapo-
ration. Generally, 1 cycle consists of 30 min and 96 cycles,
which is considered one round. Using 10μg/ml of rHaPrP as a
substrate, we performed PMCA (ePMCA, Ilsong PMCA, and
Misonix S-4000 devices) with 100-fold diluted 263K scrapie-
infected brain homogenates (10−6 to 10−28) in conversion
buffer. The ePMCA reaction was performed in thin-wall 1-
ml glass tubes. We made a slight modification to the PMCA
experimental conditions described previously [17]. We chose
a complex of piezoelectric elements, such as PbO, TiO2, ZrO2,
Sb2O3, Nb2O5, and MnO2, among ceramic piezoelectric ele-
ments to use as an ultrasonic transducer. We designed a con-
verter that emits 20 kHz and controls the output power from 0
to 2000 W if a 60-Hz electric signal is applied. We also fabri-
cated a booster and a horn of titanium. To improve the existing
PMCA, we designed an BIlsong PMCA^ device for maintain-
ing the temperature of the cup horn via a water circulation
system with a protection box. Additionally, we checked the
temperature of the water tank in real time as we installed the
temperature sensor in the cup-horn water tank.
Detection of PrPSc by Western Blot
Infected brain tissues were treated with proteinase K (PK;
50~200 μg/ml final concentration; for 30 min at 45 °C in a
shaker at 150 rpm). Additionally, we compared the PK resis-
tance of brain PrPSc in the different conditions by changing the
concentration of PK, the temperature regime of the proteinase
K treatment, and the anti-prion antibodies (3F4 and 3F10)
[19]. An insoluble fraction of brain tissue extract from a ham-
ster or a mouse infected with the scrapie strain was heated at
100 °C for 10 min and electrophoresed (15% acrylamide gels)
at 80 V. After electroblotting and applying a blocking buffer
(5% skim milk in Tris-buffered saline (TBS); 1 h at room
temperature), the nitrocellulose membranes were washed in
TBS containing 0.05% Tween-20 (TBST) and incubated with
anti-prion monoclonal antibodies (3F10 or 3F4, 1:3000 in
TBST) and then with a horseradish peroxidase-conjugated
secondary antibody in TBST containing 5% skim milk for
1 h at room temperature. At the end of each step, the mem-
branes were washed four times for 10 min with TBST, and
then the blots were visualized using a SuperSignal chemilu-
minescent substrate (Thermo Fisher, USA). The expression
levels of each protein were quantified by densitometric anal-
ysis (Image Quant LAS 4000 mini, GE Healthcare, USA).
Results
Implementation of the Improved PMCA (Ilsong
and ePMCA)
To check the change of temperature during the PMCA reaction,
we performed conventional PMCA (Misonix S-4000) in an air-
cooling incubator at 37 °C for 10 to 15 consecutive days and
monitored the water temperature in the cup horn.We found that
the water temperature immediately increased to 50~60 °C after
10cycles (datanot shown),whichmayaffect prionamplification
in the later rounds of PMCA. Therefore, to maintain the water
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temperature during the conventional PMCA reaction, we
installed awater-cooling system (a heating andwater circulation
system) that could control the water temperature in the cup horn
by circulating the water through the horn (Ilsong PMCA). In
addition, we applied electric current to the Ilsong PMCA device
via water circulation system, which we termed ePMCA (Figs. 1
and2).Thehorn in theePMCAdevicewasmadeof titanium,and
aconverterwasalsomadeof titaniumtocarry thestrongoutput to
the horn. The plastic tube that is generally used in conventional
PMCA reactions was replaced with a glass tube in the ePMCA
reaction to increase the transmissibility of cavitation.We sought
tominimize thedifferential prionamplification ineachglass tube
in theePMCAreactionbycurving the topof thecuphorn (Fig. 2)
and thus finally developed an advanced ePMCA device to cata-
lyze protein misfolding reactions (Fig. 1).
Detection of PrPSc in the Scrapie-Infected Brains
Prior to starting the PMCA,we tested for the presence of PrPSc
in ME7 and 263K scrapie-infected brain homogenates (BHs)
byWesternblotanalysis.PrPScaccumulationwasdetectedwith
the 3F10antibody inboth theME7-infected and263K-infected
BHs (data not shown), whereas none was detected in normal
brain homogenate (NBH) (Fig. 3). Two concentrations of brain
tissues (0.1 or 0.5%BH) obtained from theME7-infectedmice
were treatedwithPKatconcentrationsof50,100,or200μg/ml.
WedetectedPK-truncatedPrPSc in the infected brains,whereas
PrPCwascompletelydegraded in thenormalbrains (Fig. 3).We
observed a similar pattern of PrPSc bands in both brain prepara-
tions (0.1 or 0.5%BH) (Fig. 3).
The Influence of the Buffer Solution and Surfactant
on the Rate of PrPSc Amplification
We investigated whether prion amplification can be influ-
enced by the chemical compounds in the buffer solution
in PMCA reactions by examining the differences in prion
amplification based on the buffer solution. We performed
one round of PMCA in various buffer compositions using
the Ilsong PMCA device with ME7-infected BH as a seed
and mouse NBH as a substrate (Fig. 4). As shown in
Fig. 4a, when PBS containing NaCl, EDTA, and a com-
plete protease inhibitor cocktail with 1% Triton X-100 (2),
a nonionic surfactant, was used in the PMCA reaction,
amplified PrPSc in the ME7-infected BH was observed.
However, there was no amplification in the PBS-only
buffer (1) or in the PBS buffer with 1% SDS (3) as one
of the nonionic surfactants. Fig. 4b (1) shows a weaker
band when PMCA was conducted upon adding 1%
deoxycholic acid (1), a negative ion surfactant that has a
steroid structure, than when Triton X-100 was used
(Fig. 4a (2)). As shown in Fig. 4b (2), upon using 1%
HEPES in PMCA, there was a stronger band compared
to the use of deoxycholic acid and a weaker band
Fig. 1 A photograph of the
ePMCA device. We developed an
improved PMCA device, termed
ePMCA, that delivers an electric
current. The device is composed
of a DC power supply, an
ultrasonic generator, a water
circulator, an ultrasonic converter
system, and a protection case
Fig. 2 A diagram showing the installation of the cup horn, the tube plate,
and the electric equipment in the ePMCA device. DC 24 V/30 Welectric
current (electrode +/−, a) is delivered during the period of incubation for
the ePMCA reaction but not during the period of sonication. The cub horn
in the ePMCA is hemispherically cross-sectioned (b)
Mol Neurobiol
compared to the use of Triton X-100. Fig. 4b (3) shows
that PrPSc in the ME7-infected BH was more efficiently
amplified by 50 mM HEPES with 1% Triton X-100 than
with any other buffer composition. These results indicate
that the effectiveness of prion amplification was improved
when 50 mM HEPES with 1% Triton X-100 was used as
Fig. 3 PK-resistant PrPSc was
detected in the ME7-infected
mouse brain. Western blotting
was performed to test for the
presence of PrPSc in the ME7-
infected BH. Lane 1 0.05%NBH,
lanes 2–4 10% NBH, lane 5
0.05% ME7 BH, lanes 6–8 0.1%
ME7 BH, lanes 9–11 0.5% ME7
BH. PK(+), PK treated; PK(−),
PK untreated. Molecular masses
are indicated at the left side of the
figure (kDa). Seventy
micrograms/thirty microliters of
total protein was loaded for each
lane
Fig. 4 The effect of the buffer
solution and the surfactant on the
amplification of PrPSc derived
fromME7-infected mouse brains.
After ME7-infected mouse brains
were individually homogenized
in the buffers [a (1) PBS, (2) 1%
Triton X-100 (PBS + 1% Triton
X-100), and (3) 1% SDS (PBS +
1% SDS); b (1) 1% deoxycholate
(PBS + 1% deoxycholate), (2) 1%
HEPES (PBS + 1% HEPES), and
(3) 50 mMHEPES and 1% Triton
X-100], the homogenates were
diluted by 10−4-fold to 10−6-fold
with the same individual buffer.
The diluted homogenates were
used as prion seeds with the
indicated buffer as the conversion
buffer using mouse NBH as a
substrate in the Ilsong PMCA
device for one round, and then
PrPres was checked. Lane 1: 10−3-
fold diluted ME7 BH was not
subjected to PK digestion and
PMCA. Lane 2~10: PK treated
(100 μg/ml). Molecular masses
are given on the left of each figure
(kDa)
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the PMCA conversion buffer. We thus used the 50 mM
HEPES with 1% Triton X-100 in the PMCA reactions
described hereafter.
Ultra-sensitive Detection of PrPSc by ePMCA
Using BH of an ME7-infected mouse as a prion seed and
mouse NBH as a substrate of prion conversion, we com-
pared the efficiency of the infectious PrP amplification of
the two devices, the conventional PMCA device and the
new PMCA (Ilsong PMCA) device designed by us. When
we used the conventional PMCA device, we detected re-
sistant PrP to PK treatment in the second round (2R, 96 h)
but not in the first round (1R, 48 h) (Fig. 5b). However,
upon using the Ilsong PMCA device, we detected PK-
resistant PrP (PrPres) in the first round of the reactions
in all diluted ME7 BH (10−4- to 10−8-fold) (Fig. 5a).
The PrPres was detected in the 10−3-fold diluted BH of
the ME7-infected mouse that was not subjected to
PMCA (0 round) but not in the 10−4- to 10−7-fold diluted
BHs (left of Fig. 5a). These observations indicated that
the Ilsong PMCA device could induce better prion ampli-
fication than the conventional PMCA device.
Then, we compared the efficiency of PrP amplifica-
tion among the three devices (Misonix S-4000, Ilsong
PMCA, and ePMCA devices) using 263K-infected BH
as a prion seed and rHaPrP as a substrate for 1.5
rounds. The three devices made it possible to amplify
10−20-fold diluted 263K-infected BH, and thus, one
form of PrPres between 6 and 17 kDa was detected,
even though the intensities of the PrPres were variable
(Fig. 6). As shown in Fig. 6, compared to the Ilsong
and Misonix S-4000 devices, the ePMCA device
showed a stronger PrPres amplification at the same con-
centration of the seed (10−6- to 10−20-fold diluted 263K-
infected BH). These observations indicated that PrPres
formation occurred much more efficiently in the
ePMCA device.
To check the effect of the electric current on the PMCA
reaction, we had PrPSc in the 263K-infected BH amplified for
Fig. 5 The Ilsong PMCA device
improved the amplification of
PrPSc. Brain homogenates
(10% wt/vol) prepared from
ME7-infected mice in the
terminal stage of scrapie were
tenfold diluted with the 50 mM
HEPES buffer from 1 × 10−3 to
1 × 10−8. The resulting NBH
(10% wt/vol) extracted from
healthy mice in HEPES buffer
was used as the substrate in the
PMCA reactions [Ilsong PMCA
(a) and Misonix S-4000 PMCA
(b)]. Samples (10−4 to 10−8 seeds)
were subjected to one or two
rounds of PMCA using the Ilsong
and Misonix S-4000 devices.
ME7 BH that was not subjected to
PMCAwas diluted by 10−3- to
10−7-fold with 50 mM HEPES
buffer containing 1% Triton
X-100 as shown in the left figure
of the panel a. All samples were
treated with PK (150 μg/ml).
Lane 1 of a indicates 0.5%mouse
NBH (20 μg/30 μl). PK(+), PK
treated; PK(−), PK-untreated.
The samples were probed with the
anti-PrP monoclonal antibody
3F10. Molecular mass markers
are indicated in kilodalton on the
left
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1.5 rounds (72 h) using rHaPrP as a substrate in the presence
or absence of electricity in the ePMCA device. After PMCA
without applying the electric current (sonication for 1 min
every 30 min, 144 cycles, no electric current), one form of
PrPres between 6 and 17 kDa was clearly detected to the
10−22-fold diluted 263K BH but very faintly detected in the
10−24- to 10−28-fold diluted BH (Fig. 7a). However, in the
presence of the electric current, the form with the same size
between 6 and 17 kDa was detected even in the 10−28-fold
diluted 263K BH (Fig. 7b). These observations indicate that
the electric current markedly strengthened the prion amplifi-
cation in the ePMCA reaction.
Discussion
In the present study, we demonstrate for the first time that the
prion amplification via PMCA can be improved by applying
an electric current to the PMCA device. The application of
electricity increased the amplification rate of PK-resistant pri-
on protein at a concentration of 10−28 within 1.5 rounds
(Fig. 5b). The ePMCA device made it possible to detect the
PK-resistant prion isoform in 10−28-fold diluted BH compared
to detection in 10−20-fold diluted BH by the Ilsong PMCA
device and detection in 10−20-fold diluted BH by the
Misonix S-4000 PMCA device (Fig. 6). These results indicate
that the ePMCA device allows for more efficient prion con-
version and amplification of trace of pathogenic prion protein
in the brain tissue used as a prion seed compared to conven-
tional PMCA devices. As a result, because the best prion
amplification was achieved by using ePMCA, ePMCA can
be a useful device for detecting trace amounts of PrPSc in body
fluids, such as the cerebrospinal fluid, blood, and urine.
Fig. 6 The ultra-efficiency of the ePMCA device to detect PrPSc. 263K-
infected hamster brain was homogenized and then 100-fold diluted from
10−6 to 10−20. PMCA was performed using the ePMCA (a), Ilsong
PMCA (b) or Misonix S-4000 (c) devices. The diluted 263K BH was
tested in 10μg/ml of rHaPrP as a substrate. In lanes 1~8 in each panel, 1.5
rounds of PMCA (ePMCA, Ilsong, and S-4000 devices) were performed
in 10−5- to 10−19-fold diluted 263K BH (10 μl) with 10 μg/ml of rHaPrP
(90 μl). All samples were digested with PK (10 μg/ml for 1 h at 37 °C)
and analyzed using the 3F4 antibody. Molecular masses (kDa) are given
on the left
Fig. 7 Electric current improved
the rate of PrPSc amplification.
263K-infected hamster brain was
homogenized and then 100-fold
diluted by 10−6- to 10−28-fold.
PMCAwas conducted in the
absence (a) or presence (b) of the
electric current in the ePMCA
devices. In lanes 1~12 in each
panel, 1.5 rounds of PMCAwere
performed using the 10−5- to
10−27-fold diluted 263K BH
(10 μl) with 10 μg/ml of rHaPrP
(90 μl). All samples were
digested with PK (10 μg/ml for
1 h at 37 °C) and analyzed using
the 3F4 antibody. Molecular
masses (kDa) are given on the left
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Here, we demonstrated that the appropriate modification of
the incubation process of in vitro prion amplification, i.e., the
application of electricity, dramatically accelerates PrPSc am-
plification in the 263K strain. In addition, we also sought to
test whether prion conversion can be chemically affected. The
results showed that the conversion of PrPC to PrPSc proceeded
more easily upon adding buffer solutions with sulfonic acid
and carboxylic acid functional groups at concentrations rang-
ing from 50 to 500 mM compared to that obtained by using
PBS. This observation may be due to the increased solubility
of PrPSc upon use of a nonionic surfactant because PrPSc
structurally has low solubility and a high rate of β-sheets. In
this study, the efficiency of prion amplification increased the
most when 50 mM HEPES buffer with 1% Triton X-100 was
used as the ePMCA conversion buffer. Additionally, to solve
the problem of the tube position-dependent variation in the
prion amplification caused by each tube receiving slightly
different sonication power, which frequently occurs in con-
ventional PMCA devices, we modified the upper side of the
horn to have a curved cross-section in the ePMCA device.
Thus, the ePMCA device equipped with a curved horn can
be used as a new diagnostic tool that allows for ultra-sensitive
detection of PrPSc even in short rounds of ePMCA when
HEPES buffer is used as a conversion buffer. ePMCA also
makes it possible to hypersensitively detect PrPSc in less
rounds (1.5 rounds, 72 h) than in conventional PMCA, which
was reflected by the stronger intensity of the PrPres band
(Fig. 6). The results of our study show that under optimal
PMCA conditions (sonication and modified incubation with
an electric current), ePMCA is capable of detecting PrPSc in
scrapie-infected BH diluted by 10−28-fold as the seed within a
maximum of 1.5 reaction rounds. Using the conventional
PMCA device, the temperature of the water in the cup horn
increased to 50~60 °C immediately after sonication (data not
shown), which may result in protein modification. To avoid
protein modification at high temperatures, we developed two
PMCA devices (Ilsong PMCA and ePMCA) that allow for the
temperature of the water in the cup horn be kept constant by
using a water circulation system. Furthermore, to increase
cavitation, we used a glass sample tube, and the upper side
of the cup horn was curved in the ePMCA device.
It remains unclear how electricity influences prion conver-
sion, but we hypothesize that the process of incubation with
electricitymight help accelerate the rate of efficient conversion
of PrPC to PrPres, making prion conversion conditions more
optimal than in the other PMCA reactions without electricity.
In contrast, the presence of electricity may help rearrange the
PrPSc propagation and, thus, may induce the breakdown of
PrPSc polymer particles. Although the ePMCA device helps
improve the sensitivity of prion detection in body fluids, such
as human CSF or tears, the mechanism by which electricity is
involved in prion propagation remains to be elucidated. In this
study, we developed the world’s first early diagnostic method
forpriondiseases, the ePMCAdevice,whichmaybecapableof
detecting traces of pathogenic prion protein in prion-infected
fluids. Therefore, we suggest that the development of a diag-
nostic method that can diagnose probable CJD patients or ani-
malsusingbodyfluidsamples is themostpromisingstrategyfor
controlling the spread of the disease.
In conclusion, our findings suggest that ultra-sensitive de-
tection of the PrPSc can be achieved using ePMCA. Even trace
amounts of PrPSc can be detected using the new device, show-
ing the superiority of the ePMCA device to detect PrPSc at
higher sensitivities than any other PMCA device and further
increasing the likelihood of the development of realistic diag-
nostics for CJD and BSE.
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